Doesn’t look good for the insulin-bong:
“I think Pfizer will wish they had never gotten into this. I doubt they’ll regain their investment,” says Dr. John Buse, president-elect of the American Diabetes Association, who participated in Exubera’s trials. “There is no advantage to Exubera and there may be a safety risk. I see it as my job to talk people out of (using) it.”
ADVERTISEMENT
Get free updates delivered free to your inbox.
Search thousands of physician, PA, NP, and CRNA jobs now.
Comments are moderated before they are published. Please read the comment policy.
